Rhinomed Limited

Rhinomed is an ASX listed (RNO:AU) Melbourne Australia based medical technology firm that has developed a patented nasal and respiratory technology platform capable of radically improving the way you breathe, sleep, maintain your health and take medication. The Company is focused on solving clear, unmet needs in the global sport and exercise, sleep, wellness and drug delivery markets. Rhinomeds management team and board consists of experienced professionals from the biotech, medical, consumer health and global consumer goods industries. Our strategy is to build a significant customer base consisting of consumers, patients and clinicians, who use the platform technology across a range of applications. Mute is a compelling solution to major unmet needs in the global sleep aid market which was valued at $54.9b in 2013. By increasing the volume of air traveling through the nose during sleep, alleviating congestion and encouraging nasal breathing, Mute has been shown to not only ...